If you would like to be considered for a clinical trial you will require a referral from your current treating team.
Visit the Joining a Clinical Trial page for referral information.
For more information on clinical trials, get in contact with our cancer clinical trials enquiry coordinator.
Clinical Trials Enquiry Coordinator
Business hours, Mon to Friday between 9am - 2pm
- Email: Clinical Trials Enquiries
- Phone: (03) 8559 7456
Open and Recruiting Clinical Trials
EXPERT
A randomised trial examining use of personalised radiation therapy after breast conserving surgery in patients with low-risk early breast cancer
Cancer type
Low-risk early breast cancer
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.
Brief summary
As a standard treatment, patients with low risk breast cancer have surgery to remove the tumour followed by radiotherapy and hormonal treatment to improve the chances of cancer not returning. Doctors do not know whether it is safe to omit radiotherapy treatment in these patients to prevent over treating them. The trial aims to improve personalised use of radiation therapy in early breast cancer patients, according to their individual risk of the cancer reoccurring. The results from EXPERT trial will help doctors decide the most effective and safest approach and what treatment to recommend in the future.
Patients participating in this trial will be randomly allocated to one of two treatment groups:
- Group A: Radiotherapy and endocrine therapy
- Group B: Endocrine therapy only
Who can participate
Women aged 50 years or older who have undergone surgery to remove hormone receptor positive early breast cancer and is prescribed to receive radiotherapy and hormonal therapy as part of standard treatment.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
NINJA
Novel Integration of new prostate radiation therapy schedules with adjuvant androgen deprivation
Cancer type
Intermediate or low-high risk Prostate cancer
Status
Open and recruiting
Phase
Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Brief summary
NINJA Trial compares the effectiveness of two schedules of radiotherapy for the treatment of patients with prostate cancer. The trial aims to improve the accuracy and quality of radiotherapy treatment in prostate cancer. The trial will also look at better ways in which we can plan radiotherapy treatment for men with prostate cancer using Magnetic Resonance Imaging (MRI scans) for radiotherapy planning.
Patients participating in this trial will be randomly allocated to one of two prostate radiation therapy schedules:
- Group A: Stereotactic Body Radiotherapy (SABRT) Monotherapy
- Group B: Virtual High Dose Rate Brachytherapy (HDRB) Boost combined with a shorter version of conventional external beam radiotherapy
Who can participate
Men aged 18 years or older who have been diagnosed with unfavourable intermediate or high risk prostate cancer. The cancer has not spread to other parts of the body. The tumour will be measured on a MRI scan to plan for radiotherapy treatment.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
OUTRUN
A randomised trial of Osimertinib with or without stereotactic radiosurgery for EGFR mutated Non-Small Cell Lung Cancer with brain metastases
Cancer type
EGFR mutated Non-small Cell Lung Cancer (NSCLC) with brain metastases
Status
Open and recruiting
Phase
Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Brief summary
For people who have NSCLC with up to ten brain metastases, this study aims to determine how well these brain metastases can be controlled by a medication called Osimertinib, given with or without Stereotactic Radiosurgery (SRS).
Eligible patients will be randomly assigned to one of two treatment groups:
- Group 1: Osimertinib (1 tablet daily)
- Group 2: Stereotactic Radiosurgery (SRS) followed by Osimertinib (1 tablet daily)
Who can participate
- Adults with advanced non-small cell lung cancer (NSCLC) with EGFR mutation that has spread to the brain (brain metastases)
- These brain metastases need to be considered suitable for treatment with Stereotactic Radiosurgery (SRS) and/or Osimertinib
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
ROAM
Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial
Cancer type
Atypical menigioma
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.
Brief summary
Patients with atypical meningiomas have surgery to remove the tumour, but there is a possibility that atypical meningiomas can regrow. Doctors still do not know what is the most effective and the safest treatment approach for atypical meningioma patients following surgery.
Patients participating in this trial will be randomised to one of two treatment groups:
- Group A: Surgery, Radiotherapy and Active Monitoring
- Group B: Surgery and Active Monitoring
This study is to find out which is the most effective and the safest approach and help doctors decide what treatment to recommend in the future.
Who can participate
Adults with newly diagnosed atypical meningioma who have undergone gross total surgical resection, and who meet the all the eligibility criteria.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
STABLE-MATES
A randomised Phase III Study of Sublobar Resection (SR) versus Stereotactic Ablative Radiotherapy (SABR in High Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC)
Cancer type
Non-small cell Lung Cancer (NSCLC)
Status
Open and recruiting
Phase
Three: A phase three clinical trial follows a phase two, in a larger group of patients with specific cancer types. The aim of a phase three is to compare the new treatment to what is available for that cancer type.
Brief summary
This trial is being done to compare the results of two standard treatments for early stage NSCLC:
- Treatment A: sublobar resection (removal of a small portion of a lung)
- Treatment B: SABR (Stereotactic Ablative Radiotherapy)
The aim of this study is to determine if radiotherapy treatment (SAbR) improves patient survival over having a sublobar resection (SR) in high risk, operable, Stage I NSCLC.
Who can participate
Adults who have operable Stage 1 Non-Small Cell Lung Cancer (NSCLC) who are considered ‘high risk’ as determined by their doctor because of the condition of their heart and lungs.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
TOPGEAR
A randomised phase II/III trial evaluating preoperative chemoradiotherapy versus preoperative chemotherapy in patients undergoing adequate surgery for resectable gastric cancer.
Cancer type
Gastric Cancer
Status
Open and recruiting
Phase – Two/Three: A phase two/Three clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Brief summary
Although in developed countries the incidence of gastric cancer has dramatically decreased, gastric cancer is still a leading cause of cancer-related deaths worldwide. Surgery is the only potentially curative treatment. Although the survival rates for patients with early stage disease (stage 1A and 1B) are good, this subgroup of patients constitutes only 20% of those undergoing resection. Most patients have locally advanced or metastatic disease at presentation. The current 5-year survival rate for gastric cancer in Western countries is 20-30%, which has improved little over the past 30 years.
The primary objective of TOPGEAR is to investigate whether addition of chemoradiotherapy to neoadjuvant chemotherapy is superior to chemotherapy alone in improving the pathological complete response rates, and subsequently for overall survival.
Who can participate
Patients with resectable gastric cancer suitable for these treatments.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
TRAPEzE
Characterising co-positive breast cancer with sequential fluorine based Position Emission Tomography and Magnetic Resonance Imaging
Cancer type
Breast cancer co-positive for ER and Her-2
Status
Open and recruiting
Phase
Observational
Brief summary
TRAPEzE study compares the effectiveness of different Imaging techniques (MRI, FDG and FES PET) for characterising tumour volume in patients with ER and HER-2 co-positive breast cancer. FDG-PET, FES-PET and MRI imaging are performed at two time points (before and after systemic therapy).
Who can participate
Women aged 18 years or older who have been diagnosed with breast cancer that is ER and HER-2 positive. Patients are prescribed systemic therapy, surgery and radiotherapy as standard clinical practice. Patients in this study need to be willing and able to undergo additional study imaging.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Local HER-O
A Phase II study of local therapy only (stereotactic radiosurgery and/or surgery) for treatment of up to 5 brain metastases from HER2 positive Breast Cancer
Cancer type
Metastatic breast
Status
Open and recruiting
Phase
Two: A phase two clinical trial follows a phase one, in a large group of patients with selected cancer types. The aim of a phase two is to find out if the new treatment is effective in these cancer types.
Brief summary
This study is looking at how well tumours in the brain are controlled by stereotactic radiosurgery (SRS) and or neurosurgery (NS). The treatment offered will be determined by the patient’s doctor in consultation with the site multidisciplinary team and will be dependent on the size and location of the brain metastases. Each treatment will be performed by the specialist in that field, i.e. neurosurgeon and/or radiation oncologist.
Who can participate
Women who have Human Epidermal Growth Factor Receptor Type 2 (HER2) positive breast cancer, which has metastasised to the brain.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Lung Cancer Biomarkers Study
Lung cancer biomarkers study
Cancer type
Lung Cancer
Status
Open and recruiting
Phase
Observational
Brief summary
This trial is looking at whether lung cancer cells enter into the bloodstream during radiotherapy, and whether the presence or number of these cells can predict if the cancer will spread. A series of blood samples will be taken before, during and after radiotherapy.
Who can participate
Patients who:
- Have non-small cell lung cancer
- Are receiving radiotherapy either alone, in combination with chemotherapy, or as SABR
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.